Therapeutic re-activation of protein phosphatase 2A in acute myeloid leukemia

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Ramaswamy, Kavitha ^a   Spitzer, Barbara ^a   Kentsis, Alex ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Enzyme activation; Gene expression; Kinase signaling; Leukemia; protein phosphatase 2A

Indexed keywords

ANTINEOPLASTIC AGENT; CALCINEURIN; FINGOLIMOD; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OP449; PERPHENAZINE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SPHINGOSINE KINASE 1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOSTERISM; BREAST CARCINOMA; CANCER THERAPY; CHROMOSOME TRANSLOCATION; DOWN REGULATION; DRUG ACTIVATION; DRUG INACTIVATION; ENZYME INHIBITION; EXON; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HAPLOINSUFFICIENCY; HUMAN; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ANALYSIS;

EID: 84923256998     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00016     Document Type: Review

References (50)

1. Sontag E. Protein phosphatase 2A: the Trojan horse of cellular signaling. Cell Signal (2001) 13(1):7-16. doi:10.1016/S0898-6568(00)00123-6
2. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 353(Pt 3):417-39. doi:10.1042/0264-6021:3530417
3. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene (2005) 24(52):7746-55. doi:10.1038/sj.onc.1209038
4. Sablina AA, Hahn WC. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev (2008) 27(2):137-46. doi:10.1007/s10555-008-9116-0
5. Götz J, Probst A, Ehler E, Hemmings B, Kues W. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Ca. Proc Natl Acad Sci U S A (1998) 95(21):12370-5. doi:10.1073/pnas.95.21.12370
6. Götz J, Schild A. Transgenic and knockout models of PP2A. In: Klumpp S, Krieglstein J, editors. Methods in Enzymology. (Vol. 366), New York: Academic Press (2003). p. 390-403.
7. Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev (1993) 73(4):673-99.
8. Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, Fan E, et al. Structure of the protein phosphatase 2A holoenzyme. Cell (2006) 127(6):1239-51. doi:10.1016/j.cell.2006.11.033
9. Suganuma M, Fujiki H. [Tumor promotion by inhibitors of protein phosphatase 1 and 2A]. Tanpakushitsu Kakusan Koso (1998) 43(8 Suppl):1102-10.
10. Fujiki H, Suganuma M. Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds. Adv Cancer Res (1993) 61:143-94. doi:10.1016/S0065-230X(08)60958-6
11. Cho US, Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature (2007) 445(7123):53-7. doi:10.1038/nature05351
12. Groves MR, Hanlon N, Turowski P, Hemmings BA, Barford D. The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell (1999) 96(1):99-110. doi:10.1016/S0092-8674(00)80963-0
13. Hemmings BA, Adams-Pearson C, Maurer F, Muller P, Goris J, Merlevede W, et al. Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry (1990) 29(13):3166-73. doi:10.1021/bi00465a002
14. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 19(9):1191-5. doi:10.1038/sj.onc.1203389
15. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene (2001) 20(15):1892-9. doi:10.1038/sj.onc.1204279
16. Wang DH, Ishii K, Seno E, Yane S, Horike T, Yamamoto H, et al. Reduced serum levels of ALT and GGT and high carbohydrate intake among workers exposed to toluene below the threshold limit values. Ind Health (1998) 36(1):14-9. doi:10.2486/indhealth.36.14
17. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res (2005) 65(18):8183-92. doi:10.1158/0008-5472.CAN-05-1103
18. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 486(7403):346-52. doi:10.1038/nature10983
19. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med (2008) 12(1):241-57. doi:10.1111/j.1582-4934.2008.00249.x
20. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol (2013) 88(1):16-23. doi:10.1002/ajh.23339
21. Deichmann M, Polychronidis M, Wacker J, Thome M, Naher H. The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res (2001) 11(6):577-85. doi:10.1097/00008390-200112000-00004
22. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 106(31):12974-9. doi:10.1073/pnas.0811267106
23. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 368(22):2059-74. doi:10.1056/NEJMoa1301689
24. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2013) 29(1):15-21. doi:10.1093/bioinformatics/bts635
25. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol (2010) 11(10):R106. doi:10.1186/gb-2010-11-10-r106
26. Sallman D, Wei S, List A. PP2A: the Achilles heal in MDS with 5q deletion. Frontiers in Oncology (2014) 4:264.
27. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science (1992) 257(5074):1261-4. doi:10.1126/science.1325671
28. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 8(5):355-68. doi:10.1016/j.ccr.2005.10.015
29. Favre B, Zolnierowicz S, Turowski P, Hemmings BA. The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo. J Biol Chem (1994) 269(23):16311-7.
30. Low ICC, Loh T, Huang Y, Virshup DM, Pervaiz S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56d stabilizes its antiapoptotic activity. Blood (2014) 24(14):2223-34. doi:10.1182/blood-2014-03-563296
31. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell (2007) 130(1):51-62. doi:10.1016/j.cell.2007.04.044
32. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol (2011) 18(3):857-65. doi:10.1245/s10434-010-1313-8
33. De P, Carlson J, Leyland-Jones B, Dey N. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget (2014) 5(13):4581-602. doi:10.1126/scisignal.2004088
34. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem (1996) 271(19):11059-62. doi:10.1074/jbc.271.19.11059
35. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I(2)(PP2A)/SET. FEBS Lett (2011) 585(17):2653-9. doi:10.1016/j.febslet.2011.07.020
36. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood (2010) 115(3):615-25. doi:10.1182/blood-2009-06-227363
37. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica (2012) 97(4):543-50. doi:10.3324/haematol.2011.050542
38. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013) 45(1):18-24. doi:10.1038/ng.2495
39. Jiang L, Stanevich V, Satyshur KA, Kong M, Watkins GR, Wadzinski BE, et al. Structural basis of protein phosphatase 2A stable latency. Nat Commun (2013) 4:1699. doi:10.1038/ncomms2663
40. Prickett TD, Brautigan DL. The alpha4 regulatory subunit exerts opposing allosteric effects on protein phosphatases PP6 and PP2A. J Biol Chem (2006) 281(41):30503-11. doi:10.1074/jbc.M601054200
41. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia (2011) 25(4):606-14. doi:10.1038/leu.2010.294
42. Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, del Puerto-Nevado L. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta (2014) 1842(9):1823-9. doi:10.1016/j.bbadis.2014.06.032
43. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2013) 5(1):105-21. doi:10.1002/emmm.201201283
44. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res (2010) 70(13):5438-47. doi:10.1158/0008-5472.CAN-09-2544
45. Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem (2012) 113(4):1314-22. doi:10.1002/jcb.24003
46. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 123(10):4144-57. doi:10.1172/JCI68951
47. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene (2011) 30(22):2504-13. doi:10.1038/onc.2010.622
48. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res (2014) 20(8):2092-103. doi:10.1158/1078-0432.CCR-13-2575
49. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest (2014) 124(2):644-55. doi:10.1172/JCI65093
50. Sangodkar J. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest (2012) 122(7):2637-51. doi:10.1172/JCI62058